<div id="readability-page-1"><p>Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities researchers at HC Wainwright lowered their FY2030 earnings estimates for Crinetics Pharmaceuticals in a research note issued to investors on Friday, May 8th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $2.65 per share for the year, down from their previous forecast of $2.98. The consensus estimate for Crinetics Pharmaceuticals' current full-year earnings is ($4.95) per share.</p><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.01). Crinetics Pharmaceuticals had a negative return on equity of 43.96% and a negative net margin of 2,747.18%.The company had revenue of $10.73 million during the quarter, compared to the consensus estimate of $8.51 million. During the same quarter last year, the firm earned ($1.04) EPS. The business's revenue for the quarter was up 2873.4% on a year-over-year basis. </p><p>Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Crinetics Pharmaceuticals from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research note on Saturday. Lifesci Capital upgraded Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a research report on Friday, February 13th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a research report on Monday, January 12th. Finally, Citizens Jmp reduced their target price on shares of Crinetics Pharmaceuticals from $97.00 to $95.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Friday. One research analyst  has rated the stock with a Strong Buy rating, eight have given a Buy rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Crinetics Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $76.50.</p><p><b>Get Our Latest Analysis on CRNX</b></p><h2>Crinetics Pharmaceuticals Stock Performance</h2><p>Shares of CRNX opened at $37.48 on Monday. The business's fifty day moving average price is $38.41 and its two-hundred day moving average price is $43.89. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -7.31 and a beta of 0.28. Crinetics Pharmaceuticals has a 52 week low of $25.83 and a 52 week high of $57.99. </p><h2>Insiders Place Their Bets</h2><p>In other Crinetics Pharmaceuticals news, CEO Richard Scott Struthers sold 21,981 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $37.37, for a total value of $821,429.97. Following the transaction, the chief executive officer owned 404,778 shares of the company's stock, valued at approximately $15,126,553.86. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeff E. Knight sold 85,163 shares of the firm's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $40.10, for a total value of $3,415,036.30. Following the transaction, the insider owned 105,289 shares in the company, valued at approximately $4,222,088.90. This trade represents a 44.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 142,380 shares of company stock worth $5,569,475 over the last three months. Insiders own  3.80% of the company's stock. </p><h2>Institutional Trading of Crinetics Pharmaceuticals</h2><p>Institutional investors and hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of  Crinetics Pharmaceuticals by 55.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 852,258 shares of the company's stock valued at $30,935,000 after acquiring an additional 303,281 shares during the period.  SEB Asset Management AB acquired a new position in  Crinetics Pharmaceuticals during the first quarter valued at approximately $7,769,000.  Principal Financial Group Inc. increased its stake in  Crinetics Pharmaceuticals by 32.3% in the first quarter. Principal Financial Group Inc. now owns 7,066 shares of the company's stock valued at $257,000 after purchasing an additional 1,725 shares in the last quarter.  Teachers Retirement System of The State of Kentucky increased its stake in  Crinetics Pharmaceuticals by 4.0% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 28,477 shares of the company's stock valued at $1,034,000 after purchasing an additional 1,100 shares in the last quarter.  Finally, Fifth Third Bancorp acquired a new stake in  Crinetics Pharmaceuticals in the first quarter worth $126,000. 98.51% of the stock is owned by institutional investors. </p><h2>About Crinetics Pharmaceuticals</h2> (Get Free Report)<p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.  </p><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Crinetics Pharmaceuticals</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li><li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRNX

LABU

SBIO

<p>HC Wainwright has revised its FY2030 earnings estimate for Crinetics Pharmaceuticals (NASDAQ:CRNX), lowering it from $2.98 to $2.65 per share. The consensus estimate for the company's current full-year earnings stands at ($4.95) per share. Crinetics reported a quarterly loss of ($1.23) EPS, slightly missing expectations. The company experienced a significant revenue increase of 2873.4% year-over-year, totaling $10.73 million. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average price target of $76.50. Insiders have sold shares recently, indicating potential concerns.</p>

HC Wainwright Has Negative Estimate for CRNX FY2030 Earnings